All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Following the American College of Rheumatology annual meeting (ACR Convergence 2022), the Lupus Hub was pleased to speak to Murray Urowitz, University of Toronto, Toronto, CA. We asked, What were the key communications on lupus at ACR 2022?
Key communications on lupus at ACR 2022
In this podcast, Urowitz discusses five new therapies for lupus, as presented at ACR 2022, including deucravacitinib, litifilimab, zetomipzomib, telitacicept, and CAR T-cell agents. Urowitz outlines the mechanism of action for these therapies, highlighting the specific pathways targeted by different agents. Urowitz then provides data from clinical trials assessing these therapies and discusses their potential applications in lupus. Urowitz concludes by discussing two existing biologics, anifrolimab and voclosporin, and discussing 3-year follow up data in terms of the long-term efficacy and safety of these established treatments.
Visual abstract | The TULIP trials: Post hoc analysis of sustained glucocorticoid tapering with anifrolumab management of SLE
A visual abstract representing data from a post hoc analysis of the phase III TULIP-1 and TULIP-2 trials (NCT02446912 and...
Management of general systemic lupus erythematosus
This article summarizes the 2019 recommendations for the management of SLE, along with recent developments from subsequent clinical trials.
Subscribe to get the best content related to lupus delivered to your inbox